Substance / Medication

Pirfenidone

Overview

Active Ingredient
pirfenidone
RxNorm CUI
1592254

Indications

Pirfenidone capsules are indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

Labeler: AvKAREUpdated: 2026-01-14T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

5 trials linked to this intervention

5
Total Trials
0
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and Safety of Pirfenidone for Mitigation of Interstitial Lung Abnormalities in COVID-19 Patients: A Meta-Analysis.
Zhang Ziyi, Fang Xiang, Gao Jinhui et al. · Can Respir J · 2026
PMID: 41522210Meta-AnalysisFull text (PMC)
Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.
Amati Francesco, Stainer Anna, Polelli Veronica et al. · Int J Mol Sci · 2023
PMID: 37175556Meta-AnalysisFull text (PMC)
Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Ghazipura Marya, Mammen Manoj J, Bissell Brittany D et al. · Ann Am Thorac Soc · 2022
PMID: 35499847Meta-Analysis
Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.
Di Martino Enrica, Provenzani Alessio, Vitulo Patrizio et al. · Ann Pharmacother · 2021
PMID: 33054319Meta-Analysis
The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review.
Zang Chenchen, Zheng Yan, Wang Yanqing et al. · Eur J Med Res · 2021
PMID: 34717762Meta-AnalysisFull text (PMC)
Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis.
Shi Hanyu, Yin Dawei, Bonella Francesco et al. · BMC Pulm Med · 2020
PMID: 32380989Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pirfenidone (substance)
SNOMED CT
439581000
UMLS CUI
C0298067
RxNorm CUI
1592254
Labeler
AvKARE

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
5
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.